ストックスクリーナーアプリを入手
0.641
7.21%
-0.0498
アフターアワーズ：
.69
0.049
+7.64%
前日終値:
$0.6908
開ける：
$0.699
24時間の取引高:
263.71K
Relative Volume:
0.21
時価総額：
$2.55M
収益：
$202.00K
当期純損益:
$-28.96M
株価収益率:
-1.0683
EPS:
-0.6
ネットキャッシュフロー:
$-21.85M
1週間 パフォーマンス:
-35.25%
1か月 パフォーマンス:
-47.89%
6か月 パフォーマンス:
-74.13%
1年 パフォーマンス:
+387.94%
1日の値動き範囲:
$0.6141
$0.7029
1週間の範囲:
$0.6141
$0.98
52週間の値動き範囲:
$0.0632
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Compare AIM vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.641 | 2.75M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
AIM ImmunoTech Inc (AIM) 最新ニュース
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Bitget
AIM ImmunoTech (AIM) Projects $1.8M from Rights Offering - GuruFocus
Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million - TradingView
AIM ImmunoTech raises $1.8M with $1,000 preferred stock and warrant bundles - Stock Titan
AIM ImmunoTech Signs Agreement for Planning of a Proposed - GlobeNewswire
AIM Collaborates with Thermo Fisher for Phase 3 Trial of Amplige - GuruFocus
AIM ImmunoTech Inc. has signed an agreement to plan a proposed Phase III clinical trial of its core candidate drug Ampligen for the treatment of advanced pancreatic cancer. - Bitget
Experimental pancreatic cancer drug Ampligen moves toward Phase 3 test - Stock Titan
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer - Sahm
AIM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AIM ImmunoTech (AIM) Updates Rights Offering Terms - GuruFocus
Investors get $1,000 AIM unit with 2,000 warrants — but clock is ticking - Stock Titan
AIM ImmunoTech (NYSE American: AIM) offers 12,000 Units and 24M warrants - Stock Titan
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - Sahm
AIM Should I Buy - Intellectia AI
AIM ImmunoTech (AIM) Extends Rights Offering Subscription Period - GuruFocus
AIM ImmunoTech Inc. recently announced that it will extend the exercise period for shareholder subscription rights in its previously announced stock offering plan. - Bitget
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 - The Manila Times
Aim Immunotech Announces Extension Of Subscription Period - TradingView
AIM cancer-drug investors get new March 3 deadline, use-it-or-lose-it rights - Stock Titan
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi - Indian Pharma Post
AIM ImmunoTech (AIM) Reports Progress in Pancreatic Cancer Study - GuruFocus
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - Bitget
AIM ImmunoTech Announces Planned Milestones in the Ongoing - GlobeNewswire
New pancreatic cancer trial pairs AIM drug with AstraZeneca's Imfinzi - Stock Titan
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer - ChartMill
AIM ImmunoTech at Virtual Investor Closing Bell: Strategic Focus on Pancreatic Cancer By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
AIM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Merger Talk: Will AIM ImmunoTech Inc. stock outperform global peersEarnings Beat & Verified Chart Pattern Trade Signals - mfd.ru
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - The Manila Times
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - The Manila Times
Pancreatic cancer drug strategy: AIM ImmunoTech CEO in Feb. 19 live webcast - Stock Titan
AIM ImmunoTech at Corporate Connect: Ampligen’s Role in Pancreatic Cancer - Investing.com Canada
AIM: Ampligen demonstrates strong survival and quality of life benefits in late-stage pancreatic cancer - TradingView
AIM ImmunoTech launches rights offering to raise $12 million - Intellectia AI
AIM ImmunoTech Launches Rights Offering for Common Stock Holders - GuruFocus
Aim Immunotech Announces Commencement Of Rights Offering - TradingView
AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewswire
Cancer drug developer AIM ImmunoTech seeks $12M from shareholders - Stock Titan
ImmunoTech (AIM) updates S-1 with exhibits-only Amendment No. 3 - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
AIM ImmunoTech to Participate in Corporate Connect Webinar - Intellectia AI
AIM ImmunoTech to Participate in the Corporate Connect - GlobeNewswire
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - 富途牛牛
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted ... - Herald and News
AIM ImmunoTech Eyes $12M Funding Boost with Rights Offering - timothysykes.com
AIM ImmunoTech Inc. (AIM) stock: surges as pancreatic cancer trial shows survival breakthrough - parameter.io
AIM ImmunoTech reports year-end positive phase 2 interim progress for Ampligen® (rintatolimod) plus AstraZeneca's Imfinzi® (durvalumab) in pancreatic cancer - marketscreener.com
AIM ImmunoTech Inc (AIM) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):